Oruka Therapeutics, Inc. $ORKA Shares Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lifted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 10.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 603,479 shares of the company’s stock after purchasing an additional 58,117 shares during the period. Affinity Asset Advisors LLC’s holdings in Oruka Therapeutics were worth $6,765,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ORKA. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the 2nd quarter worth about $28,000. Ameritas Investment Partners Inc. purchased a new position in shares of Oruka Therapeutics in the second quarter valued at approximately $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Oruka Therapeutics in the second quarter worth approximately $68,000. New York State Common Retirement Fund acquired a new stake in shares of Oruka Therapeutics in the second quarter worth approximately $96,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Oruka Therapeutics during the second quarter worth approximately $168,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Wednesday, October 8th. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Thursday, November 13th. They issued a “buy” rating and a $45.00 target price for the company. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. BTIG Research upped their price objective on shares of Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, Barclays began coverage on shares of Oruka Therapeutics in a research note on Monday, October 13th. They issued an “overweight” rating and a $48.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $45.14.

Oruka Therapeutics Stock Down 0.3%

ORKA stock opened at $30.84 on Friday. Oruka Therapeutics, Inc. has a 52-week low of $5.49 and a 52-week high of $31.80. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -16.23 and a beta of -0.41. The business has a fifty day moving average of $26.62 and a two-hundred day moving average of $18.20.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.